According to the absolute value of each lymphocyte subgroup (Table 2), the expression level of CD4+ TSCM in the CRC group was 4.01 (2.32–5.86), which significantly differed from that in the benign tumor group and healthy control group (Figure 2A). This evidence concerns the gene CD4 and benign neoplasm.